Status:
COMPLETED
Cardioprotective Effects of Endogenous Erythropoietin in Patients Undergoing Coronary Artery Bypass Surgery
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Conditions:
Cardiac Surgery
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Several studies have highlighted the cardioprotective effects of acute normovolemic hemodilution during cardiac surgery. The aim of our study is to show that an increase in endogenous erythropoietin (...
Detailed Description
The major physiologic function of EPO is thought to be the induction of erythropoiesis. However, a growing body of evidence indicates that EPO has tissue-protective effects and prevents tissue damage ...
Eligibility Criteria
Inclusion
- patients between 18 and 80 years old undergoing CABG with or without cardiopulmonary bypass
Exclusion
- emergencies
- redo operations
- combined surgery
- men with Hb\< 120g/dL and women with Hb\< 110g/ dL
- patients with preoperative creatinine\> 2.2 mg/dL
- poor ventricular function (EF \< 50%)
- subjects with a pulmonary disease, hepatic disease
- subjects with carotid stenosis
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00854217
Start Date
March 1 2009
End Date
December 1 2010
Last Update
March 3 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cliniques Universitaires saint Luc
Brussels, Belgium, 1200